Changing the end point like Gilead did get them EUA so, we may get EAU and also have to continue to 390 at the same time, who knows, IDK but with an advanced immunomodulator like Leronlimab is and being it's way different than Rem, anything can happen. Sorry, just my hunch and a way for the fda to escape or avoid embarrassment - GLTU calstang

HCIT